薄型子宫内膜在单基因病植入前遗传学检测患者中更常见且与既往激素避孕使用相关吗
回顾性病例对照研究纳入122例单基因病植入前遗传学检测(PGT-M)患者和240例匹配对照,比较hCG触发日子宫内膜厚度。PGT-M组子宫内膜<8 mm的比例为32% vs 对照组11%(均差21.0%,95%CI 11.7-30.3%),晚期停用激素避孕(<1年)为64% vs 2%,既往激素避孕使用时长10.6年 vs 9.3年;晚期停用(OR 6.0)和使用时长(每增加1年OR 1.1)为薄型子宫内膜的独立危险因素。
要点
- PGT-M组hCG触发日子宫内膜<8 mm比例为32%,显著高于对照组的11%。
- PGT-M组64%在治疗前<1年停用激素避孕,对照组仅2%。
- 晚期停用激素避孕(OR 6.0)和既往使用时长(每增加1年OR 1.1)为薄型子宫内膜独立危险因素。
核心结论
- 薄型(<8 mm)子宫内膜在PGT-M患者中较常规IVF/ICSI人群更常见,且与更长的既往激素避孕使用时长及更短的停用间隔相关。
研究设计与样本
- 回顾性病例对照研究,纳入2009年至2018年格罗宁根大学医学中心所有PGT-M患者(病例),按年龄和治疗时期1:2匹配非PGT的IVF/ICSI患者作为对照。
- 共纳入122例PGT-M患者和240例对照的首次周期。
主要发现
- hCG触发日子宫内膜<8 mm在PGT-M组为32% vs 对照组11%(均差21.0%,95%CI 11.7-30.3%)。
- 晚期停用激素避孕(<1年)在PGT-M组为64% vs 对照组2%(均差61.9%,95%CI 53.0-70.8%)。
- 既往激素避孕平均使用时长为PGT-M组10.6年 vs 对照组9.3年(均差1.3年,95%CI 0.2-2.3年)。
- 多因素logistic回归显示晚期停用(OR 6.0,95%CI 1.9-19.2)和既往激素避孕使用时长(每增加1年OR 1.1,95%CI 1.0-1.2)为薄型子宫内膜的显著独立危险因素。
- PGT-M组中子宫内膜<8 mm者流产率为20.0% vs 子宫内膜>8 mm者1.7%(均差18.3%,95%CI 2.3-34.3%);该组还观察到出生体重及经孕周和性别校正的出生体重(z评分)有降低趋势;妊娠率、活产率、早产或小于胎龄儿发生率无统计学显著差异;对照组内子宫内膜<8 mm与>8 mm者结局无统计学显著差异。
临床怎么用
- 作者认为,未来研究应提供更多关于其临床相关性的信息,以确定PGT-M患者能否被安抚,或应被建议在PGT治疗前停止激素避孕并改用其他避孕方法。
局限性
- 研究为回顾性。
- 报告的激素避孕类型多样,可能对子宫内膜产生不同影响。
- 与妊娠结局指标相关的数量非常有限,因此不应得出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is a thin endometrial lining before ovulation triggering more prevalent in patients utilizing preimplantation genetic testing for monogenic disease (PGT-M) compared to the regular IVF/ICSI population and is this associated with prior hormonal contraceptive use? SUMMARY ANSWER: Thin (<8 mm) endometrial lining is more prevalent in PGT-M patients compared to the regular IVF/ICSI population and is associated with both longer prior hormonal contraceptive use and a shorter cessation interval of hormonal contraceptives before IVF/ICSI treatment. WHAT IS KNOWN ALREADY: Thin endometrial lining has been associated with lower pregnancy rates in IVF/ICSI cycles and increased chances of miscarriage and low birth weight. Endometrial thinning and atrophy occur during hormonal contraceptive use. Patients utilizing PGT-M typically use hormonal contraceptives up until treatment to avoid the risk of conception of a genetically affected child. Whether this could negatively affect endometrial thickness achieved during subsequent IVF/ICSI cycles is not known. STUDY DESIGN, SIZE, DURATION: A retrospective case control study was performed, including all PGT-M patients attending the University Medical Centre Groningen (cases), between 2009 and 2018. The control group consisted of two non-PGT IVF/ICSI patients for each PGT-M patient, matched for age and treatment period. PARTICIPANTS/MATERIALS, SETTING, METHODS: First cycles of 122 PGT-M patients and 240 controls were included. Cessation interval of hormonal contraceptives was categorized as late cessation (cessation <1 year prior to treatment) or early cessation (>1 year prior to treatment). Endometrial thickness was routinely measured on the day of hCG triggering or 1 day prior. The prevalence of an endometrial lining <8 mm was compared between PGT-M patients and controls. Hormonal contraceptive use (both duration and cessation interval) was compared between both groups. Univariable and multivariable regression analyses were performed to identify risk factors for thin endometrial lining. In addition, cycle and pregnancy outcomes were compared within control/PGT-M groups between patients with endometrial lining > or <8 mm. MAIN RESULTS AND THE ROLE OF CHANCE: Thin endometrial lining on the day of hCG triggering was found significantly more often in the PGT-M group, compared to controls: 32% vs 11% (mean difference 21.0%, 95% CI: 11.7, 30.3%). As expected, more patients in the PGT-M group ceased their hormonal contraception late (<1 year): 64% vs 2% in the control group (mean difference 61.9%, 95% CI: 53.0, 70.8%). Average duration of hormonal contraceptive use was 10.6 years in the PGT-M group vs 9.3 years in controls (mean difference 1.3 years, 95% CI: 0.2, 2.3 years). Multivariable logistic regression analysis identified late cessation (OR: 6.0, 95% CI: 1.9-19.2) and duration of prior hormonal contraceptive use (OR per year increase 1.1, 95% CI: 1.0-1.2) as significant independent risk factors for a thin endometrial lining. In relation to outcome, we found a statistically significant increase in miscarriage rate in PGT-M patients with an endometrial lining <8 mm compared to those with an endometrial lining >8 mm (20.0% vs 1.7%, mean difference 18.3%, 95% CI: 2.3, 34.3%). A trend towards lower birth weight and gestation- and gender-adjusted birth weight (z-score) was also found in this group. No statistically significant differences were detected in pregnancy rate, live birth rate, or incidence of preterm delivery or SGA. Within the control group, no statistically significant differences were found in outcomes between patients with an endometrial lining <8 compared to an endometrial lining >8 mm. LIMITATIONS, REASONS FOR CAUTION: The study is retrospective. Various types of hormonal contraceptives were reported which possibly exert different effects on the endometrial lining. In relation to pregnancy outcome measures, numbers were very limited; therefore, no firm conclusions should be drawn. WIDER IMPLICATIONS OF THE FINDINGS: This study provides further insight into the role of prior hormonal contraceptive use as a possible contributor to the occurrence of thin endometrial lining during ART treatment. Future studies should provide more information on its clinical relevance, to determine whether PGT-M patients can be reassured, or should be counselled to stop hormonal contraceptive use and change to an alternative contraceptive method prior to PGT treatment. STUDY FUNDING/COMPETING INTERESTS: No specific funding was used and no conflicts of interests are declared. TRIAL REGISTRATION NUMBER: N/A.
引用
- Homminga I, Ter Meer AF, Groen H, et al. Thin endometrial lining: is it more prevalent in patients utilizing preimplantation genetic testing for monogenic disease (PGT-M) and related to prior hormonal contraceptive use? Hum Reprod. 2023. PMID: 36478464. doi:10.1093/humrep/deac258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。